Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Peter SchmidJavier CortesRebecca DentHeather McArthurLajos PusztaiSherko KümmelCarsten DenkertYeon Hee ParkRina HuiNadia HarbeckMasato TakahashiSeock-Ah ImMichael UntchPeter A FaschingMarie-Ange Mouret-ReynierTheodoros FoukakisMarta FerreiraFatima CardosoXuan ZhouVassiliki KarantzaKonstantinos TryfonidisGursel AktanJoyce O'Shaughnessynull nullPublished in: The New England journal of medicine (2024)
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab resulted in a significant improvement, as compared with neoadjuvant chemotherapy alone, in overall survival among patients with early-stage triple-negative breast cancer. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).